This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| TPP1 | |
|---|---|
| Name | Tripeptidyl-peptidase 1 |
| Alt | Lysosomal enzyme TPP1 |
TPP1 is a lysosomal serine protease involved in oligopeptide degradation and protein turnover. It functions within the endolysosomal system and influences neuronal homeostasis, autophagy, and apoptosis. Mutations produce a recessive neurodegenerative phenotype with systemic manifestations that has been studied across human genetics, developmental biology, and translational medicine.
The protein is encoded by a gene on human chromosome 11 and comprises a signal peptide, propeptide, and mature catalytic domain similar to members of the peptidase family. Structural studies using X-ray crystallography and cryo-EM compared the fold to other lysosomal enzymes characterized in datasets from the European Molecular Biology Laboratory, the Protein Data Bank, and laboratories at institutions such as Massachusetts Institute of Technology, University of Cambridge, University of Oxford, Harvard Medical School. Sequence conservation analyses cite orthologs identified by projects at the National Institutes of Health, European Bioinformatics Institute, and GenBank entries curated alongside annotations from the Human Genome Project. Exon–intron architecture and promoter elements were mapped using resources from ENCODE, UCSC Genome Browser, and sequencing centers at Cold Spring Harbor Laboratory; comparative genomics referenced model organisms studied at the Max Planck Institute, Stanford University, and Karolinska Institutet.
TPP1 functions as a lysosomal exopeptidase releasing tripeptides from N-termini of substrates and contributes to catabolic pathways cataloged in the KEGG and Reactome databases. Biochemical characterization used methods from laboratories at Johns Hopkins University, Yale University, and University of California, San Francisco to determine pH optimum, catalytic residues, and substrate specificity; assays employed reagents standardized by the American Chemical Society and instrumentation from Thermo Fisher Scientific. TPP1 activity intersects with lysosomal acid hydrolases such as enzymes catalogued by the International Union of Biochemistry and Molecular Biology and modulates processes studied in cell biology reports published in journals associated with Nature Publishing Group and Cell Press.
Expression profiling across tissues utilized data from the Genotype-Tissue Expression Project, microarray studies at Affymetrix, and RNA-seq datasets deposited in repositories managed by the European Nucleotide Archive and Sequence Read Archive. Developmental regulation was examined in collaborations involving National Institute of Child Health and Human Development and developmental biology groups at Massachusetts General Hospital and Boston Children's Hospital. Transcriptional control elements were analyzed in chromatin immunoprecipitation experiments referencing factors studied at Cold Spring Harbor Laboratory and EMBL-EBI, while post-translational modifications and trafficking signals were elucidated in cell trafficking studies from laboratories at University College London and Imperial College London.
Loss-of-function mutations cause a neurodegenerative lysosomal storage disorder first characterized in clinical series reported by pediatric neurology groups at Children's Hospital of Philadelphia, Great Ormond Street Hospital, and Mayo Clinic. The phenotype overlaps with disorders described in case reports from Johns Hopkins Hospital, Stanford Medical Center, and international centers such as Sheba Medical Center and SickKids Hospital. Diagnostic protocols reference criteria from organizations including the American Academy of Neurology and biochemical confirmatory testing used by clinical laboratories accredited by College of American Pathologists. Therapeutic strategies under investigation include enzyme replacement trials coordinated through networks such as European Reference Networks and gene therapy studies developed at translational centers like University of Pennsylvania and biotechnology companies collaborating with regulatory agencies such as the Food and Drug Administration.
TPP1 participates in lysosomal protein interaction networks mapped in large-scale proteomics efforts by consortia at ProteomeXchange, CERN Microbiology-linked labs, and collaborations between Max Delbrück Center and pharmaceutical partners. It interfaces with trafficking machinery studied in work from Yale School of Medicine, including interactions affecting mannose-6-phosphate receptor pathways first described in research from Rockefeller University and trafficking defects analyzed using tools from European Molecular Biology Laboratory. Pathway integration includes crosstalk with autophagy regulators characterized at MIT, and apoptotic pathways researched at Cold Spring Harbor Laboratory and Dana-Farber Cancer Institute.
Animal models include knockout and knock-in alleles generated in mice by teams at The Jackson Laboratory, rat models at National Institute of Neurological Disorders and Stroke, and zebrafish studies from groups at University of Oregon and Karolinska Institutet. Phenotyping platforms used protocols from the International Mouse Phenotyping Consortium and behavioral assessments developed at Columbia University and University of California, Berkeley. Preclinical studies of gene therapy employed viral vectors developed at Vector Biolabs and translational pipelines linked to clinical centers such as Mayo Clinic and Cleveland Clinic. High-throughput screening for modulators referenced compound libraries from Sigma-Aldrich and assay development led by teams at GlaxoSmithKline and Pfizer.
Category:Lysosomal enzymes